Completed NA INTERVENTIONAL 1-arm NCT05122585

Magnetic Tracer in the Sentinel Node Procedure in Breast Cancer: the Non-radioactive Alternative for Radio-isotopes (MagTrace)

Sponsor: Sysmex America, Inc.

Interventions MagSeed and MagTrace in breast cancer patiënts

Updated 5 times since 2021 Last updated: Mar 31, 2022 Started: Aug 1, 2021 Primary completion: Feb 9, 2022 Completion: Feb 9, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Breast Cancer, this trial is completed. The trial is conducted by Sysmex America, Inc. and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
May 2022 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed
Mar 2022 — May 2022 [monthly]

Recruiting NA
Dec 2021 — Mar 2022 [monthly]

Recruiting NA

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sysmex America, Inc.
Zuyderland Medisch Centrum

Data source: Zuyderland Medisch Centrum

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sittard, Netherlands